艾拉莫德对原发性干燥综合征患者ESR、CRP和免疫球蛋白水平的影响

Effects of iguratimod on ESR,CRP and immunoglobulin levels in patients with primary Sjogren’s syndrome

目的:探讨艾拉莫德在原发性干燥综合征(pSS)治疗中的应用价值。方法:应用随机数字表法,将60例pSS患者分为对照组及联合组各30例。对照组进行常规西药治疗,联合组在此基础上联合艾拉莫德治疗,对比两组临床治疗效果。结果:治疗过程中,两组的ESSDAI、ESSPRI、ESR、CRP、IgG、IgA及IgM水平均较治疗前呈降低趋势(P<0.05)。治疗8周及16周后,联合组的ESSDAI评分、ESSPRI评分、ESR、CRP、IgG、IgA及IgM水平均低于对照组(P<0.05);治疗16周后,联合组的治疗总有效率明显高于对照组(P<0.05);而两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:艾拉莫德可有效改善pSS患者临床症状和免疫球蛋白水平,有利于提高其临床治疗效果。

Objective:To analyze the application value of iguratimod in the treatment of primary Sjogren’s syndrome(pSS).Methods:Sixty patients with pSS were randomly divided into a control group and a combined group with 30 cases each.The control group was treated with conventional western medicine,while the combined group treated with both iguratimod and conventional western medicine.The clinical effect was compared between the two groups.Results:During the treatment process,the disease activity index of Sjogren’s syndrome(ESSDAI)scores,report index of Sjogren’s syndrome(ESSPRI)scores,erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),immunoglobulin G(IgG),immunoglobulin A(IgA)and immunoglobulin M(IgM)levels in the two groups showed a trend of decrease compared with the levels before treatment(P<0.05).After 8 weeks and 16 weeks of treatment,the ESSDAI and ESSPRI scores and the levels of ESR,CRP,IgG,IgA and IgM were lower in the combined group than the control group(P<0.05).Meanwhile,after 16 weeks of treatment,the total effective rate was significantly higher in the combined group than the control group(P<0.05),while there were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Iguratimod can improve the clinical symptoms and immunoglobulin level,which is beneficial to improving the clinical therapeutic effect of pSS.